Small nucleolar RNA host gene 1 (SNHG1) facilitates gemcitabine chemosensitivity in gallbladder cancer by regulating the miR-23b-3p/phosphatase and tensin homolog (PTEN) pathway.
10.1097/CM9.0000000000003482
- Author:
Hui WANG
1
;
Yixiang GU
2
;
Miaomiao GUO
3
;
Ming ZHAN
3
;
Min HE
1
;
Yang ZHANG
1
;
Linhua YANG
1
;
Yingbin LIU
1
Author Information
1. Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
2. Shanghai Key Laboratory of Systems Regulation and Clinical Translation for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
3. The Core Laboratory in Medical Center of Clinical Research, Shanghai Ninth People's Hospital, State Key Laboratory of Medical Genomics, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
- Publication Type:Journal Article
- Keywords:
Chemoresistance;
Gallbladder cancer;
Phosphatase and tensin homolog (PTEN);
Small nucleolar RNA host gene 1 (SNHG1);
miR-23b-3p
- MeSH:
Humans;
Deoxycytidine/pharmacology*;
PTEN Phosphohydrolase/genetics*;
Gemcitabine;
RNA, Long Noncoding/metabolism*;
MicroRNAs/genetics*;
Gallbladder Neoplasms/genetics*;
Cell Line, Tumor;
Animals;
Mice;
Drug Resistance, Neoplasm/genetics*;
Mice, Nude;
Antimetabolites, Antineoplastic;
Gene Expression Regulation, Neoplastic
- From:
Chinese Medical Journal
2025;138(21):2783-2792
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Growing evidence suggests that long non-coding RNAs (lncRNAs) exert pivotal roles in fostering chemoresistance across diverse tumors. Nevertheless, the precise involvement of lncRNAs in modulating chemoresistance within the context of gallbladder cancer (GBC) remains obscure. This study aimed to uncover how lncRNAs regulate chemoresistance in gallbladder cancer, offering potential targets to overcome drug resistance.
METHODS:To elucidate the relationship between gemcitabine sensitivity and small nucleolar RNA host gene 1 ( SNHG1 ) expression, we utilized publicly available GBC databases, GBC tissues from Renji Hospital collected between January 2017 and December 2019, as well as GBC cell lines. The assessment of SNHG1, miR-23b-3p, and phosphatase and tensin homolog (PTEN) expression was performed using in situ hybridization, quantitative real-time polymerase chain reaction, and western blotting. The cell counting kit-8 (CCK-8) assay was used to quantify the cell viability. Furthermore, a GBC xenograft model was employed to evaluate the impact of SNHG1 on the therapeutic efficacy of gemcitabine. Receiver operating characteristic (ROC) curve analyses were executed to assess the specificity and sensitivity of SNHG1.
RESULTS:Our analyses revealed an inverse correlation between the lncRNA SNHG1 and gemcitabine resistance across genomics of drug sensitivity in cancer (GDSC) and Gene Expression Omnibus (GEO) datasets, GBC cell lines, and patients. Gain-of-function investigations underscored that SNHG1 heightened the gemcitabine sensitivity of GBC cells in both in vitro and in vivo settings. Mechanistic explorations illuminated that SNHG1 could activate PTEN -a commonly suppressed tumor suppressor gene in cancers-thereby curbing the development of gemcitabine resistance in GBC cells. Notably, microRNA (miRNA) target prediction algorithms unveiled the presence of miR-23b-3p binding sites within SNHG1 and the 3'-untranslated region (UTR) of PTEN . Moreover, SNHG1 acted as a sponge for miR-23b-3p, competitively binding to the 3'-UTR of PTEN , thereby amplifying PTEN expression and heightening the susceptibility of GBC cells to gemcitabine.
CONCLUSION:The SNHG1/miR-23b-3p/PTEN axis emerges as a pivotal regulator of gemcitabine sensitivity in GBC cells, holding potential as a promising therapeutic target for managing GBC patients.
